Doris Alexandra Schuetz

Doris Alexandra Schuetz

Auto-generated profile, based on publicly available information

Doris Alexandra Schuetz

Institute for Research in Immunology and Cancer, Laboratory of Intracellular Signaling, Université de Montréal, Montreal, QC, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2018 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
DSDoris Alexandra Schuetz
Doris Alexandra Schuetz
MBMattia Bernetti
Mattia Bernetti
MBMartina Bertazzo
Martina Bertazzo
DMDjordje Musil
Djordje Musil
HEHans-Michael Eggenweiler
Hans-Michael Eggenweiler
ACAndrea Cavalli
Andrea Cavalli

27 April 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DSDoris Alexandra Schuetz
Doris Alexandra Schuetz
LRLars Richter
Lars Richter
MAMarta Amaral
Marta Amaral
MGMelanie Grandits
Melanie Grandits
UGUlrich Graedler
Ulrich Graedler
GEGerhard Ecker
Gerhard Ecker

29 May 2025 in Science
Verified
Journal Article
Closed access
HLHugo Lavoie
Hugo Lavoie
TJTing Jin
Ting Jin
DLDriss Lajoie
Driss Lajoie
MDMarion Decossas
Marion Decossas
PGPatrick Gendron
Patrick Gendron
MTMarc Therrien
Marc Therrien
Uncontrolled activation of the rat sarcoma (RAS)–extracellular signal–regulated kinase (ERK) pathway drives tumor growth, often because of oncogenic BRAF mutations. BRAF regulation, involving monomeric autoinhibition and activation by dimerization, has been intensely scrutinized, but mechanisms enabling oncogenic mutants to evade regulation remain unclear. By using cryo–electron microscopy, we solved the three-dimensional structures of the three oncogenic BRAF mutant classes, including the common V600E variant. These mutations disrupted wild-type BRAF's autoinhibited state, mediated by interactions between the cysteine-rich domain and kinase domain, thereby shifting the kinase domain into a preactivated conformation. This structural change likely results from helix αC displacement. PLX8394, a BRAF inhibitor that stabilizes helix αC in an inactive conformation, restored the autoinhibited conformation of oncogenic BRAF, explaining the properties of this class of compounds.

21 September 2020 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
DSDoris A. Schuetz
Doris A. Schuetz
LRLars Richter
Lars Richter
RMRiccardo Martini
Riccardo Martini
GEGerhard Ecker
Gerhard Ecker
A large-scale study employing matched molecular pair (MMP) analysis to uncover the contribution of a compound's polarity to its association and dissociation rates.

3 August 2018 in Journal of Chemical Theory and Computation
Verified
Journal Article
Closed access
DSDoris Alexandra Schuetz
Doris Alexandra Schuetz
Thomas SeidelThomas Seidel
Thomas Seidel
AGArthur Garon
Arthur Garon
RMRiccardo Martini
Riccardo Martini
MKMarkus Körbel
Markus Körbel
TLThierry Langer
Thierry Langer

3 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JGJenna Giubilaro
Jenna Giubilaro
DSDoris A. Schuetz
Doris A. Schuetz
TSTomasz M. Stepniewski
Tomasz M. Stepniewski
YNYoon Namkung
Yoon Namkung
EKEtienne Khoury
Etienne Khoury
SLStephane A Laporte
Stephane A Laporte
Internalization and intracellular trafficking of G protein-coupled receptors (GPCRs) play pivotal roles in cell responsiveness. Dysregulation in receptor trafficking can lead to aberrant signaling and cell behavior. Here, using an endosomal BRET-based assay in a high-throughput screen with the prototypical GPCR angiotensin II type 1 receptor (AT1R), we sought to identify receptor trafficking inhibitors from a library of ~115,000 small molecules. We identified a novel dual Ras and ARF6 inhibitor, which we named Rasarfin, that blocks agonist-mediated internalization of AT1R and other GPCRs. Rasarfin also potently inhibits agonist-induced ERK1/2 signaling by GPCRs, and MAPK and Akt signaling by EGFR, as well as prevents cancer cell proliferation. In silico modeling and in vitro studies reveal a unique binding modality of Rasarfin within the SOS-binding domain of Ras. Our findings unveil a class of dual small G protein inhibitors for receptor trafficking and signaling, useful for the inhibition of oncogenic cellular responses.